The following evidence-based papers present research into various facets of Lyme disease, and are organized into three categories to expedite comprehension:
Cameron DJ, Johnson LB, Maloney EL. Evidence Assessments and Guideline Recommendations in Lyme Disease: The Clinical Management of Known Tick Bites, Erythema Migrans Rashes and Persistent Disease. Expert Rev Anti Infect There. 2014 Sep;12(9):1103-1135. don:10.1586/14787210.2014.940900
Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-1134.
Centers for Disease Control and Prevention (CDC). Lyme Disease (Borrelia burgdorferi) 2017 Case Definition. Council of State and Territorial Epidemiologists (CSTE) Position Statement(s)
Cameron DJ. Consequences of treatment delay in Lyme disease. J Eval Clin Pract. 2007 Jun;13(3):470-2.
Maloney EL. The management of Ixodes scapularis bites in the upper midwest. WMJ 2011 Apr;110(2):78-81.
Maloney EL. The need for clinical judgment in the diagnosis and treatment of Lyme disease. J AM Physicians Surgeons. 2009;14(3):82-89
Accuracy of Clinician Suspicion of Lyme Disease in the Emergency Department
Nigrovic LE, Bennett JE, Balamuth F, Levas MN, Chenard RL, Maulden AB, Garro AC; for Pedi Lyme Net.
Pediatrics, online first 2017 Nov 24. pii: e20171975.
Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nature Reviews Disease Primers. 2016 Dec 15;2:16090
Cameron DJ. Proof That Chronic Lyme Disease Exists. Interdisciplinary Perspectives on Infectious Diseases, vol. 2010 Article ID 876450, 4 pages, 2010. doi:10.1155/2010/876450
Crowder LA, Yedlin VA, Weinstein ER, Kortte KB, Aucott JN. Lyme disease and post-treatment Lyme disease syndrome: the neglected disease in our own backyard. Public Health. 2014;128(9):784–791.
Feng J, Wang T, Shi W, et al. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerging Microbes & Infections. 02 July 2014;3:e49. doi:10.1038/emi.2014.53.
Feng J, Shi W, Zhang S, Zhang Y. Persister mechanisms in Borrelia burgdorferi: implications for improved intervention. Emerging Microbes & Infections. 19 August 2015;4:e51. doi:10.1038/emi.2015.51.
Johnson L, Wilcox S, Mankoff J, Stricker RB. Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey. PeerJ. 2014 Mar 27;2:e322. doi: 10.7717/peerj.322.
Lobraico J, Butler A, Petrini J, Ahmadi R. New insights into stages of Lyme disease symptoms from a novel hospital-based registry. Journal of Primary Care and Community Health. 2014;5(4):284-287.
Maloney EL. Controversies in Persistent (Chronic) Lyme Disease. J Infus Nurs. 2016 Nov; 39(6): 369–375. doi:10.1097/NAN.0000000000000195.
Rebman AW, Bechtold KT, Yang T, et al. The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome. Frontiers in Medicine (Lausanne). 2017 Dec 14;4:224.
Zhang Y. Persisters, persistent infections and the Yin–Yang model. Emerging Microbes & Infections. 2014 Jan 8;3:e3. doi:10.1038/emi.2014.3